Althea Group Holdings Ltd (ASX: AGH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Althea Group Holdings Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $73.42 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 312.43 million
Earnings per share -0.061
Dividend per share N/A
Year To Date Return 4.44%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Althea Group Holdings Ltd (ASX: AGH)
Latest News

Frequently Asked Questions

Althea Group does not currently pay a dividend.

No, Althea Group doesn’t currently offer a dividend reinvestment plan (DRP).

AGH ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Althea Group Holdings Ltd

One of Australia’s ASX cannabis shares, Althea Group Holdings Limited (ASX: AGH) cultivates, produces, supplies, imports, and exports pharmaceutical grade medicinal cannabis in Australia and the United Kingdom.

Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea shares first listed on the ASX in September 2018. The AGH share price is tied to the global legal marijuana market, which has been spurred by increased legalisation and the use of marijuana in medical applications.

AGH Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
21 Jan 2022 $0.24 $0.00 0.00% 500,888 $0.23 $0.24 $0.23
20 Jan 2022 $0.24 $0.03 14.29% 585,258 $0.23 $0.24 $0.22
19 Jan 2022 $0.21 $-0.01 -4.65% 376,474 $0.22 $0.22 $0.21
18 Jan 2022 $0.22 $0.00 0.00% 184,794 $0.22 $0.22 $0.22
17 Jan 2022 $0.22 $-0.01 -4.55% 89,079 $0.22 $0.23 $0.22
14 Jan 2022 $0.22 $0.00 0.00% 175,799 $0.22 $0.22 $0.22
13 Jan 2022 $0.22 $0.00 0.00% 222,640 $0.22 $0.22 $0.22
12 Jan 2022 $0.22 $0.01 4.65% 169,146 $0.22 $0.23 $0.22
11 Jan 2022 $0.22 $-0.01 -4.44% 41,012 $0.22 $0.22 $0.22
10 Jan 2022 $0.23 $0.00 0.00% 106,268 $0.23 $0.23 $0.22
07 Jan 2022 $0.23 $0.01 4.55% 39,932 $0.22 $0.23 $0.22
06 Jan 2022 $0.22 $-0.01 -4.35% 542,194 $0.23 $0.24 $0.22
05 Jan 2022 $0.23 $0.01 4.44% 92,003 $0.23 $0.23 $0.23
04 Jan 2022 $0.23 $0.00 0.00% 199,851 $0.23 $0.24 $0.22
31 Dec 2021 $0.23 $-0.01 -4.35% 45,382 $0.23 $0.23 $0.22
30 Dec 2021 $0.23 $0.00 0.00% 176,728 $0.23 $0.23 $0.23
29 Dec 2021 $0.24 $0.00 0.00% 29,050 $0.23 $0.24 $0.23

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Jan 2021 Alan Boyd Buy 68 $30,000
Participation in share purchase plan.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Alan Maclean Boyd Non-Executive Director Jun 2018
Mr Boyd was the Chief Financial Officer of Ridley Corporation Limited, an ASX-listed provider of high performance animal nutrition solutions. Prior to his role, Mr Boyd occupied the Chief Financial Officer and Company Secretary position with listed biotechnology companies Avexa Limited and Zenyth Therapeutics Limited and website pioneer Sausage Software Limited. Mr Boyd started his professional career in chartered accounting firms in England and Australia and has broad financial experience across many industry sectors. He is Chair of Audit, Risk and Compliance Management Committee and member of Remuneration and Nomination Committee

Mr Philip Andrew Newbold Non-Executive ChairmanNon-Executive Director Jun 2018
Mr Newbold is a qualified lawyer having practised for nearly 20 years at a large commercial firm. Following his retirement from law in 2006, he founded a renewable energy business which he sold to Origin Energy in 2009. Since that time he has been involved in a start-up property app business which he sold to ANZ in 2015 and various other businesses. Mr Newbold has been a director of numerous private companies and not-for-profit organisations and currently is a director of Supra Capital, a Commissioner of the AFL and Chairman of Golf Australia. He is a Member of Audit, Risk and Compliance Management Committee & Remuneration and Nomination Committee

Mr Joshua Michael Fegan Chief Executive OfficerManaging Director Jun 2018
Mr Fegan is the founder of Althea Group Holdings Limited and has experience in business building, sales and marketing. He has a range of business and strategy skills and has previously held a number of senior management roles at national value-based retailer, Strathfield Group. Mr Fegan founded Althea Health and Wellbeing in 2016, coinciding with registration of the Narcotic Drugs Amendment Act 2016 (Cth) (ND Amendment Act), an Act to amend the Narcotic Drugs Act 1967 (Cth) (ND Act), legalising medicinal cannabis
Penelope Dobson Non-Executive Director Nov 2018
Mr Dobson is an experienced global healthcare executive. She has worked in the broad life-science space since her training as a pharmacist in New Zealand, including many years in the global pharmaceutical industry. Mr Dobson is currently a Principal at Valida Consulting, offering a range of services to companies in the healthcare, Pharma, Biotech, not-forprofit, Device and Diagnostics sector. She is Chair of Remuneration and Nomination Committee and member of Audit, Risk and Compliance Management Committee

Mr Robert Meissner Chief Financial OfficerCompany Secretary Apr 2019
-
Robert Meissner Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Joshua Michael Fegan 56,250,000 21.44%
Hsbc Custody Nominees (Australia) Limited 16,016,253 6.10%
National Nominees Limited 12,015,231 4.58%
Mancann Pty Ltd 10,000,000 3.81%
J P Morgan Nominees Australia Pty Limited 8,734,586 3.33%
Hootch Pty Ltd 7,500,000 2.86%
Oh-Rule Pty Ltd 4,763,165 1.82%
Citicorp Nominees Pty Limited 3,225,545 1.23%
Jamplat Pty Ltd 2,390,000 0.91%
Pac Partners Securities Pty Ltd 2,249,255 0.86%
Mr Hoang Huy Nguyen 2,214,161 0.84%
Mr Philip John Cawood 1,950,000 0.74%
BNP Paribas Nominees Pty Ltd 1,775,000 0.68%
Maelstrom Pty Ltd (Falkiner Super Fund A/C) 1,500,000 0.57%
Newbold Family Super Fund 1,500,000 0.57%
Mansfield Can Investments Pty Ltd (Mansfield Super Fund A/C) 1,366,035 0.52%
PAC Partners Pty Ltd 1,017,347 0.39%
Mr Anthony Karl Stani 850,000 0.32%
Emerging Equities Pty Ltd 822,300 0.31%
BNP Paribas Nominees Pty Ltd I 802,502 0.31%

Profile

since

Note